$CCEL
CRYO CELL INTERNATIONAL INC

2017 Form 10-K Financial Statement

#000119312518064199 Filed on February 28, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016
Revenue $25.38M $5.870M $23.13M
YoY Change 9.76% 1.21% 9.66%
Cost Of Revenue $6.724M $1.440M $5.775M
YoY Change 16.44% -2.04% 2.56%
Gross Profit $18.66M $4.430M $17.35M
YoY Change 7.53% 2.31% 12.24%
Gross Profit Margin 73.51% 75.47% 75.03%
Selling, General & Admin $13.48M $3.810M $14.72M
YoY Change -8.44% -0.78% 18.83%
% of Gross Profit 72.25% 86.0% 84.84%
Research & Development $41.17K $20.00K $53.10K
YoY Change -22.47% 100.0% 15.98%
% of Gross Profit 0.22% 0.45% 0.31%
Depreciation & Amortization $230.0K $70.00K $243.0K
YoY Change -5.35% 0.0% 11.47%
% of Gross Profit 1.23% 1.58% 1.4%
Operating Expenses $13.52M $3.860M $14.78M
YoY Change -8.49% -0.77% 18.82%
Operating Profit $5.006M $570.0K $433.6K
YoY Change 1054.59% 29.55% -85.22%
Interest Expense $1.303M -$140.0K $947.3K
YoY Change 37.51% -50.0% -27.34%
% of Operating Profit 26.02% -24.56% 218.49%
Other Income/Expense, Net -$1.383M $30.00K -$2.914M
YoY Change -52.55% 0.0% 48.29%
Pretax Income $3.624M $350.0K -$2.480M
YoY Change -246.1% -170.0% -361.21%
Income Tax $1.309M -$460.0K -$1.159M
% Of Pretax Income 36.11% -131.43%
Net Earnings $2.315M $810.0K -$1.321M
YoY Change -275.28% -468.18% -116.29%
Net Earnings / Revenue 9.12% 13.8% -5.71%
Basic Earnings Per Share $0.33 -$0.16
Diluted Earnings Per Share $0.30 $118.9K -$0.16
COMMON SHARES
Basic Shares Outstanding 7.063M shares 6.796M shares 8.113M shares
Diluted Shares Outstanding 7.653M shares 8.113M shares

Balance Sheet

Concept 2017 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.718M $4.120M $4.124M
YoY Change 62.91% -13.45% -13.41%
Cash & Equivalents $6.279M $3.500M $3.500M
Short-Term Investments $439.3K $620.0K $624.2K
Other Short-Term Assets $578.3K $78.45K $474.0K
YoY Change 22.01% -11.25% -76.95%
Inventory $314.6K $361.1K $361.1K
Prepaid Expenses $395.5K
Receivables $5.126M $4.053M $4.053M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.74M $9.012M $9.012M
YoY Change 41.33% -12.95% -12.95%
LONG-TERM ASSETS
Property, Plant & Equipment $882.4K $979.5K $979.5K
YoY Change -9.91% 11.42% 11.42%
Goodwill $0.00
YoY Change -100.0%
Intangibles $261.0K
YoY Change -49.45%
Long-Term Investments $0.00
YoY Change
Other Assets $10.06M $9.547M $9.286M
YoY Change 8.38% 15.5% 55.5%
Total Long-Term Assets $11.17M $10.53M $10.53M
YoY Change 6.14% 15.11% 15.11%
TOTAL ASSETS
Total Short-Term Assets $12.74M $9.012M $9.012M
Total Long-Term Assets $11.17M $10.53M $10.53M
Total Assets $23.91M $19.54M $19.54M
YoY Change 22.37% 0.21% 0.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.929M $1.485M $1.485M
YoY Change 29.83% 11.8% 11.8%
Accrued Expenses $2.582M $2.554M $2.554M
YoY Change 1.1% 27.38% 27.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M $2.000M
YoY Change 0.0% 545.16% 550.58%
Total Short-Term Liabilities $13.94M $13.11M $13.11M
YoY Change 6.32% 25.78% 25.78%
LONG-TERM LIABILITIES
Long-Term Debt $5.295M $1.425M $7.820M
YoY Change -32.28% -38.04% 799.91%
Other Long-Term Liabilities $17.18M $21.84M $14.02M
YoY Change 22.51% 55.58% 6.47%
Total Long-Term Liabilities $22.47M $23.27M $21.84M
YoY Change 2.89% 42.4% 55.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.94M $13.11M $13.11M
Total Long-Term Liabilities $22.47M $23.27M $21.84M
Total Liabilities $36.41M $34.95M $34.95M
YoY Change 4.18% 42.89% 42.89%
SHAREHOLDERS EQUITY
Retained Earnings -$26.79M
YoY Change 5.19%
Common Stock $30.47M
YoY Change 6.33%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.12M
YoY Change 129.91%
Treasury Stock Shares 5.715M shares
Shareholders Equity -$12.50M -$15.41M -$15.41M
YoY Change
Total Liabilities & Shareholders Equity $23.91M $19.54M $19.54M
YoY Change 22.37% 0.21% 0.21%

Cashflow Statement

Concept 2017 2016 Q4 2016
OPERATING ACTIVITIES
Net Income $2.315M $810.0K -$1.321M
YoY Change -275.28% -468.18% -116.29%
Depreciation, Depletion And Amortization $230.0K $70.00K $243.0K
YoY Change -5.35% 0.0% 11.47%
Cash From Operating Activities $5.718M $2.570M $4.988M
YoY Change 14.64% 29.15% 2.81%
INVESTING ACTIVITIES
Capital Expenditures $98.33K -$40.00K $343.0K
YoY Change -71.33% -33.33% 216.17%
Acquisitions
YoY Change
Other Investing Activities $191.4K -$30.00K -$26.75K
YoY Change -815.36% -83.33% -95.62%
Cash From Investing Activities $93.03K -$70.00K -$369.7K
YoY Change -125.16% -70.83% -48.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $446.6K $10.81M
YoY Change -95.87% 237.13%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.032M -1.020M -5.271M
YoY Change -42.47% 218.75% 61.71%
NET CHANGE
Cash From Operating Activities 5.718M 2.570M 4.988M
Cash From Investing Activities 93.03K -70.00K -369.7K
Cash From Financing Activities -3.032M -1.020M -5.271M
Net Change In Cash 2.779M 1.480M -652.3K
YoY Change -526.09% 3.5% -174.73%
FREE CASH FLOW
Cash From Operating Activities $5.718M $2.570M $4.988M
Capital Expenditures $98.33K -$40.00K $343.0K
Free Cash Flow $5.620M $2.610M $4.645M
YoY Change 20.99% 27.32% -2.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000 shares
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000 shares
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000 shares
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7105191 shares
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000 shares
CY2016Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
9866178
CY2016Q2 ccel Repurchases Agreement Settlement Payment In Part Through Term Loan
RepurchasesAgreementSettlementPaymentInPartThroughTermLoan
8000000
CY2017Q2 dei Entity Public Float
EntityPublicFloat
23416774
CY2016Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
1666430
CY2016Q3 ccel Intangible Asset Impaired Accumulated Impairment Loss
IntangibleAssetImpairedAccumulatedImpairmentLoss
211267
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2067130
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4152162
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-4964171
CY2016Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
223955
CY2016Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
443701
CY2016Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1267818
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2278862
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2554330
CY2016Q4 us-gaap Assets Current
AssetsCurrent
9011923
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4052728
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
32210
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6371431
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
30340573
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1485430
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34408
CY2016Q4 us-gaap Assets
Assets
19538468
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3499881
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6789596 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12504464 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
125044
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
21000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7071924
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11583000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9261000
CY2016Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9260582
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4917000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
68000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1416000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2301000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12596292
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
433000
CY2016Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
21000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
261000
CY2016Q4 us-gaap Goodwill
Goodwill
0
CY2016Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
111392
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
261000
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
261000
CY2016Q4 us-gaap Inventory Net
InventoryNet
361142
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
586646
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9100
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 us-gaap Liabilities
Liabilities
34952726
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19538468
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13111684
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
9819750
CY2016Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
7819750
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
624223
CY2016Q4 us-gaap Notes Payable
NotesPayable
10150100
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2000000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
78448
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9547082
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21841042
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
395501
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
979463
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7350894
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26789791
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.84
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
97406 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-15414258
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5714868 shares
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
330350
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19124492
CY2016Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
25500
CY2016Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1996000
CY2016Q4 ccel Deferred Tax Asset Net Operating Loss Credits And Other Carry Forward
DeferredTaxAssetNetOperatingLossCreditsAndOtherCarryForward
459000
CY2016Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1678000
CY2016Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
17000
CY2016Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
616000
CY2016Q4 ccel Inventory Collection Kits
InventoryCollectionKits
98760
CY2017Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
424782
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
356483
CY2017Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1068381
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2098991
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2582475
CY2017Q4 us-gaap Assets Current
AssetsCurrent
12736921
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5125591
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
84555
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6566846
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
31373048
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1928542
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
40865
CY2017Q4 us-gaap Assets
Assets
23909997
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6279154
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7103941 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12899517 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
128995
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
12000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7428829
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12364000
CY2017Q4 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
378785
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10036000
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
10035388
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5886000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
405000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1039000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2316000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15752864
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
711000
CY2017Q4 us-gaap Deferred Tax Liabilities Investments
DeferredTaxLiabilitiesInvestments
12000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
34582
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
34582
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
34582
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
34582
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
34582
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
226418
CY2017Q4 us-gaap Goodwill
Goodwill
0
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
226418
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
210854
CY2017Q4 us-gaap Inventory Net
InventoryNet
314566
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
97210
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
648274
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Liabilities
Liabilities
36412893
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23909997
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13939846
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
7295183
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1500100
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2000000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2000000
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5295183
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
439322
CY2017Q4 us-gaap Notes Payable
NotesPayable
7500100
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2000000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
206136
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
19087
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10290694
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22473047
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
229038
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
372152
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
882382
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7449228
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24474691
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.41
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
987811 shares
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1026979 shares
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.50
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
39168 shares
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.41
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12502896
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086 shares
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
204917
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2017Q4 ccel Finite Lived Intangible Assets Amortization Expense Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseThereafter
53508
CY2017Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
28888
CY2017Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
18000
CY2017Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1909000
CY2017Q4 ccel Deferred Tax Asset Net Operating Loss Credits And Other Carry Forward
DeferredTaxAssetNetOperatingLossCreditsAndOtherCarryForward
8000
CY2017Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1788000
CY2017 us-gaap Advertising Expense
AdvertisingExpense
1008000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
487350
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
618000
CY2017Q4 ccel Inventory Collection Kits
InventoryCollectionKits
14220
CY2017Q4 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2 CompensationPlan
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2014Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2014Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600 sqft
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2016Q1 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600 sqft
CY2017 us-gaap Adjustment For Amortization
AdjustmentForAmortization
229995
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
972000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
744233
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
971730
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
125434
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35000
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Risks</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Deposit Insurance Corporation (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company depends on three suppliers for the supply and manufacturing of the PrepaCyte CB units.&#xA0;However, the Company believes that alternative sources of supply and manufacturing are available.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> During fiscal 2017 and 2016, there were no concentration of risks.</p> </div>
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2779273
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2321557
CY2017 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
Company depends on one supplier for the source of its collection kits
CY2017 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
98000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1483000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
108000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2074000
CY2017 us-gaap Cost Of Services
CostOfServices
6724391
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
483000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
20378053
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
131614
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-318000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-774806
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-447000
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15 pure
CY2017 us-gaap Depreciation
Depreciation
230000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.372 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.031 pure
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-11-30
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.034 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
571873
CY2017 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Product Warranty and Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> Program</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#xA0;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Additionally, under the Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company&#x2019;s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company&#x2019;s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company&#x2019;s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of November&#xA0;30, 2017and November&#xA0;30, 2016 the Company recorded reserves under these programs in the amounts of approximately $18,000 and $17,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.</p> </div>
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1195000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3513477
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-73000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
179000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
119000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1149875
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-28145
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-46576
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-23349
CY2017 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
590114 shares
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3623703
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1308603
CY2017 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
108000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
443112
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
127688
CY2017 us-gaap Interest Expense
InterestExpense
1302650
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
446439
CY2017 us-gaap Licenses Revenue
LicensesRevenue
1003056
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
310970
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
93025
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
5718173
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3031925
CY2017 us-gaap Net Income Loss
NetIncomeLoss
2315100
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
5006226
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1382523
CY2017 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6457
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-79873
CY2017 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-191358
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
446621
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
98333
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
64696
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
77012
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2650000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41165
CY2017 us-gaap Revenue Recognition Services Royalty Fees
RevenueRecognitionServicesRoyaltyFees
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>License and Royalty Agreements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Company&#x2019;s technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and <font style="WHITE-SPACE: nowrap">know-how</font> in a selected area. The investor may be given a right to sell <font style="WHITE-SPACE: nowrap">sub-license</font> agreements as well. As part of the accounting for the <font style="WHITE-SPACE: nowrap">up-front</font> license fee paid, or payable, to the Company, revenue from the <font style="WHITE-SPACE: nowrap">up-front</font> license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed by the Company based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license agreement: El Salvador, Guatemala, Panama, Honduras, China and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any <font style="WHITE-SPACE: nowrap">sub-license</font> agreements that are sold by the licensee where applicable. These fees are included in processing and storage fees revenue on the consolidated statements of comprehensive income (loss). As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.</p> </div>
CY2017 us-gaap Revenues
Revenues
25384279
CY2017 us-gaap Royalty Expense
RoyaltyExpense
112830
CY2017 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
23939033
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
971730
CY2017 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y5M23D
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13480883
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
25000 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
83238 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.99
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64696
CY2017 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2017 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-82000
CY2017 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2017 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
446621
CY2017 dei Trading Symbol
TradingSymbol
CCEL
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7652984 shares
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7062870 shares
CY2017 ccel Product Revenue
ProductRevenue
442190
CY2017 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
159000
CY2017 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
3388
CY2017 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
141000
CY2017 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
589399
CY2017 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
108000
CY2017 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
1003056
CY2017 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
125434
CY2017 ccel Description On Second Amendment To Employment Agreement
DescriptionOnSecondAmendmentToEmploymentAgreement
The Amendment provides for the grant of shares of the Company's common stock based on certain performance measures being attained by the Company during fiscal year 2016. The Amendment states if Executive is employed by the Company on November 30, 2016, then no later than February 28, 2017, the Company will grant Executive up to 20,000 shares of restricted stock based on performance as set forth in the Amendment.
CY2017 ccel Contracted Storage Period Option Three
ContractedStoragePeriodOptionThree
Lifetime
CY2017 ccel Number Of License Agreement
NumberOfLicenseAgreement
2 Agreement
CY2017 ccel Number Of Licensing Agreement Made By Entity
NumberOfLicensingAgreementMadeByEntity
12 Agreement
CY2017 ccel Types Of License Agreements
TypesOfLicenseAgreements
2 Agreement
CY2017 ccel Number Of Deliverables For Revenue Recognized
NumberOfDeliverablesForRevenueRecognized
2 Deliverables
CY2017 ccel Contracted Storage Period Option Two
ContractedStoragePeriodOptionTwo
P21Y
CY2017 ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2017 ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P21Y
CY2017 ccel Contracted Storage Period Option One
ContractedStoragePeriodOptionOne
P1Y
CY2017 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.045 pure
CY2017 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.031 pure
CY2017 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
0.000 pure
CY2017 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure
CY2017 ccel Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
3000000
CY2017 ccel Income Tax Reconciliation Deferred Repricing
IncomeTaxReconciliationDeferredRepricing
343000
CY2017 ccel Effective Income Tax Rate Reconciliation Deferred Repricing
EffectiveIncomeTaxRateReconciliationDeferredRepricing
0.098 pure
CY2017 ccel Depreciation And Amortization Including Cost Of Sales
DepreciationAndAmortizationIncludingCostOfSales
229995
CY2016 us-gaap Adjustment For Amortization
AdjustmentForAmortization
286650
CY2016 us-gaap Advertising Expense
AdvertisingExpense
1186000
CY2016 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
373053
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1772000
CY2016 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
791434
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
1772306
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
48435
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
44000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-652281
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
753000
CY2016 us-gaap Cost Of Services
CostOfServices
5774800
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1456324
CY2016 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
132000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
432000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
109000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
212000
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
22694453
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
154673
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1662000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1911828
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-250000
CY2016 us-gaap Depreciation
Depreciation
243000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.477 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
-0.043 pure
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.036 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.016 pure
CY2016 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-2252388
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
300593
CY2016 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1989089
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-880000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2016436
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-329000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-94000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-40000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1624462
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
648842
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-114466
CY2016 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-32318
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2480212
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1159412
CY2016 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
109000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
329560
CY2016 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-9944
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-204344
CY2016 us-gaap Interest Expense
InterestExpense
947340
CY2016 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
277749
CY2016 us-gaap Interest Expense Debt
InterestExpenseDebt
229314
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-369728
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4987975
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-5270528
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-1320800
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
433594
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2913806
CY2016 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-135524
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14671
CY2016 us-gaap Licenses Revenue
LicensesRevenue
1006319
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
288832
CY2016 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
3400000
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
378785
CY2016 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
231090
CY2016 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10806409
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
342982
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40340
CY2016 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10783433
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
630113
CY2016 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1509107
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53097
CY2016 us-gaap Revenues
Revenues
23128047
CY2016 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
21771600
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1772306
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14722794
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.86
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40340
CY2016 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2016 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-17000
CY2016 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
10806409
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8112791 shares
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8112791 shares
CY2016 ccel Product Revenue
ProductRevenue
350128
CY2016 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
184000
CY2016 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-15111
CY2016 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
121000
CY2016 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
666138
CY2016 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
109000
CY2016 ccel Income Tax Reconciliation Valuation Allowance Release
IncomeTaxReconciliationValuationAllowanceRelease
-329000
CY2016 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
1006319
CY2016 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
48435
CY2016 ccel Effective Income Tax Rate Reconciliation Valuation Allowances
EffectiveIncomeTaxRateReconciliationValuationAllowances
0.127 pure
CY2016 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
-0.073 pure
CY2016 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
-0.043 pure
CY2016 ccel Depreciation And Amortization Including Cost Of Sales
DepreciationAndAmortizationIncludingCostOfSales
286650

Files In Submission

Name View Source Status
0001193125-18-064199-index-headers.html Edgar Link pending
0001193125-18-064199-index.html Edgar Link pending
0001193125-18-064199.txt Edgar Link pending
0001193125-18-064199-xbrl.zip Edgar Link pending
ccel-20171130.xml Edgar Link completed
ccel-20171130.xsd Edgar Link pending
ccel-20171130_cal.xml Edgar Link unprocessable
ccel-20171130_def.xml Edgar Link unprocessable
ccel-20171130_lab.xml Edgar Link unprocessable
ccel-20171130_pre.xml Edgar Link unprocessable
d497800d10k.htm Edgar Link pending
d497800dex311.htm Edgar Link pending
d497800dex312.htm Edgar Link pending
d497800dex313.htm Edgar Link pending
d497800dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g497800g0227013159339.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending